Arms Race with a Superbug
News Sep 16, 2016
If you get pneumonia, or even an infected cut, your body becomes a war zone.
And as the immune system battles invading bacteria, the outcome of that war may hinge on a microscopic arms race based on an essential element: iron.
Scientists from the University of Michigan Medical School say they have figured out how that race for iron actually increases the risk we face from one of our most dangerous microscopic foes, Klebsiella pneumoniae. They made the discovery in mice with pneumonia.
K. pneumoniae has already figured out how to overcome our best defenses – including, in some cases, all our most powerful antibiotics.
It’s the third-most-common cause of infections that arise in hospitalized patients, and causes pneumonia, urinary tract infections, wound infections and bloodstream infections. In its most drug-resistant form, it’s considered one of the carbapenem resistant Enterobacteriaceae, or CRE – so called "nightmare bacteria".
The new findings could aid the search for drugs to fight it, and other “superbugs”.
Iron scavenging – and more
In a new paper in the journal mBio, the team led by Michael Bachman, M.D., Ph.D. report what happens after the bacteria send out tiny iron-scavenging molecules.
Called siderophores, those molecules have long been thought of as a way for bacteria to gather a precious element needed to grow and reproduce, by attaching to iron and stealing it from us.
Siderophores from K. pneumoniae are hundreds of times more powerful at grabbing iron than the proteins that our own bodies produce. What’s more, the bacteria produce a kind of siderophore that our defense systems can’t neutralize.
But Bachman and his colleagues show that bacterial siderophores do much more than just grab iron. Their experiments show that K. pneumoniae actually use the molecules to help them invade the rest of the body beyond their initial point of entry, and to bring on inflammation caused by our own immune system.
“This is a bacterium that has evolved new ways to get iron, and it turns out that the mechanism it uses also causes cellular stress during infections,” says Bachman, an assistant professor of pathology at U-M. “That response triggers an immune response that tells our bodies to fight the infection, but it also activates a mechanism that allows bacteria to escape and travel to the rest of the body.”
That mechanism, a protein called Hif-1alpha, normally helps our bodies respond to low oxygen or low iron. But when K. pneumoniae siderophores activate it, it worsens the infection. Exactly how is still a mystery.
Bachman sees the effects of K. pneumoniae on patients in his work as a clinical microbiologist at the U-M Health System, where he’s associate director of clinical microbiology. That motivates him to study it in the lab, though he notes that it’s too early to say exactly how the discovery could be used to help patients.
One promising route could be to develop strategies to prevent the bacteria from sending out siderophores in the first place -- or to use the siderophores to bring antibiotics back into bacterial cells. Or, it may even be possible to create a vaccine based on siderophores to teach the immune system to attack them as invaders.
Meanwhile, he and others at U-M including Microbiology & Immunology chair Harry Mobley, Ph.D., are pursuing a broader goal through U-M’s Host Microbiome Initiative. Using an advanced genetic technique called transposon sequencing, they’re working to figure out which genes K. pneumoniae and other superbugs absolutely need in order to cause infections.
How they did it
To figure out the double role that siderophores play in a K. pneumoniae infection, Bachman and his colleagues had to figure out how to create bacteria that would not reproduce, while still producing siderophores. They were able to mutate bacteria in a way that kept iron-laden siderophores from getting back into the bacterial cells and promoting growth. That way, the number of bacteria in a mouse’s body stayed the same, but the researchers could study what the siderophores did.
They expected that if the siderophores grabbed enough iron from the mouse’s lung tissue and robbed the mouse an essential element, the mouse’s cells would respond.. Indeed, they found that the mouse immune system was triggered directly by the siderophores, causing the release of molecules called cytokines that attract infection-fighting cells and cause inflammation as a result. The activation of Hif-1alpha was part of this – because the mouse cells sensed that iron supply was low.
So, the team figured out how to eliminate Hif-1alpha in the cells lining the mouse lungs – and showed that in these mice, most of the bacteria couldn’t escape from the lungs to the spleen. But in mice that made Hif-1alpha, more K. pneumoniae bacteria spread to the rest of the body, making the infection worse.
“This work provides us with motivation to target the production of siderophores, rather than just the uptake of them,” says Bachman. “Now that we know that the bacteria cause cellular stress just by secreting them, we may be able to prevent these effects if we neutralize them.”
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE